S&P 500   3,870.29
DOW   31,391.52
QQQ   318.40
S&P 500   3,870.29
DOW   31,391.52
QQQ   318.40
S&P 500   3,870.29
DOW   31,391.52
QQQ   318.40
S&P 500   3,870.29
DOW   31,391.52
QQQ   318.40
Log in

Synlogic Stock Forecast, Price & News

+0.19 (+5.00 %)
(As of 03/2/2021 12:00 AM ET)
Today's Range
Now: $3.99
50-Day Range
MA: $4.08
52-Week Range
Now: $3.99
Volume265,832 shs
Average Volume1.46 million shs
Market Capitalization$138.99 million
P/E RatioN/A
Dividend YieldN/A
Synlogic, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of synthetic biotic medicines to treat metabolic, inflammatory, and cancer diseases in the United States. Its therapeutic programs include SYNB1618, an oral therapy that is in Phase I/IIa clinical trial to treat phenylketonuria. The company is also developing SYNB1891, an intratumorally administered synthetic biotic medicine that is in Phase I clinical trial to treat solid tumors and lymphoma. It has a collaboration agreement with Ginkgo Bioworks for the development of synthetic biotic medicines. Synlogic, Inc. is headquartered in Cambridge, Massachusetts.
Synlogic logo

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Current SymbolNASDAQ:SYBX
Year FoundedN/A



Sales & Book Value

Annual Sales$2.22 million
Book Value$4.86 per share


Net Income$-51,370,000.00
Net Margins-2,761.83%


Market Cap$138.99 million
Next Earnings Date3/11/2021 (Estimated)
OptionableNot Optionable


Overall MarketRank

1.62 out of 5 stars

Medical Sector

299th out of 1,969 stocks

Pharmaceutical Preparations Industry

146th out of 772 stocks

Analyst Opinion: 3.3Community Rank: 2.7Dividend Strength: 0.0Insider Behavior: 0.8Valuation: 1.3 5 -4 -3 -2 -1 -
+0.19 (+5.00 %)
(As of 03/2/2021 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive SYBX News and Ratings via Email

Sign-up to receive the latest news and ratings for SYBX and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles

Synlogic (NASDAQ:SYBX) Frequently Asked Questions

Is Synlogic a buy right now?

3 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Synlogic in the last year. There are currently 1 hold rating and 2 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" Synlogic stock.
View analyst ratings for Synlogic
or view top-rated stocks.

What stocks does MarketBeat like better than Synlogic?

Wall Street analysts have given Synlogic a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Synlogic wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

Are investors shorting Synlogic?

Synlogic saw a increase in short interest in February. As of February 12th, there was short interest totaling 457,600 shares, an increase of 36.8% from the January 28th total of 334,500 shares. Based on an average daily volume of 1,910,000 shares, the short-interest ratio is presently 0.2 days. Currently, 2.2% of the company's stock are sold short.
View Synlogic's Short Interest

When is Synlogic's next earnings date?

Synlogic is scheduled to release its next quarterly earnings announcement on Thursday, March 11th 2021.
View our earnings forecast for Synlogic

How were Synlogic's earnings last quarter?

Synlogic, Inc. (NASDAQ:SYBX) issued its quarterly earnings results on Thursday, November, 5th. The biotechnology company reported ($0.36) EPS for the quarter, beating the Thomson Reuters' consensus estimate of ($0.47) by $0.11. Synlogic had a negative net margin of 2,761.83% and a negative trailing twelve-month return on equity of 41.64%.
View Synlogic's earnings history

How has Synlogic's stock price been impacted by Coronavirus (COVID-19)?

Synlogic's stock was trading at $1.54 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization. Since then, SYBX stock has increased by 159.1% and is now trading at $3.99.
View which stocks have been most impacted by COVID-19

When did Synlogic's stock split? How did Synlogic's stock split work?

Synlogic shares reverse split on Monday, August 28th 2017. The 1-7 reverse split was announced on Friday, August 25th 2017. The number of shares owned by shareholders was adjusted after the market closes on Friday, August 25th 2017. An investor that had 100 shares of Synlogic stock prior to the reverse split would have 14 shares after the split.

What price target have analysts set for SYBX?

3 brokers have issued 12 month price targets for Synlogic's stock. Their forecasts range from $10.00 to $13.00. On average, they expect Synlogic's stock price to reach $11.50 in the next twelve months. This suggests a possible upside of 188.2% from the stock's current price.
View analysts' price targets for Synlogic
or view top-rated stocks among Wall Street analysts.

Who are Synlogic's key executives?

Synlogic's management team includes the following people:
  • Dr. Aoife M. Brennan M.D., MB, BCh, BAO, MMSc, Pres, CEO & Director (Age 45, Pay $737.3k)
  • Dr. Richard J. Riese M.D., Ph.D., Chief Medical Officer (Age 58, Pay $209.16k)
  • Prof. Timothy K. Lu, Co-Founder
  • Dr. James J. Collins, Co-Founder (Age 54)
  • Mr. Antoine Awad, Chief Operating Officer
  • Mr. Daniel Rosan, Head of Corp. Fin. & Investor Relations
  • Dr. David L. Hava, Chief Scientific Officer (Age 46)
  • Dr. Elizabeth Wolffe, Head of Investor Relations & Corp. Communications
  • Mr. Adam Thomas, Chief People Officer & Sec.
  • Dr. Caroline B. Kurtz Ph.D., Head of Translational Sciences & Product Devel.

Who are some of Synlogic's key competitors?

What other stocks do shareholders of Synlogic own?

What is Synlogic's stock symbol?

Synlogic trades on the NASDAQ under the ticker symbol "SYBX."

Who are Synlogic's major shareholders?

Synlogic's stock is owned by a number of retail and institutional investors. Top institutional shareholders include Dimensional Fund Advisors LP (2.82%), BlackRock Inc. (1.18%), Renaissance Technologies LLC (1.00%), Verition Fund Management LLC (0.07%), Jane Street Group LLC (0.05%) and Flagship Harbor Advisors LLC (0.05%).
View institutional ownership trends for Synlogic

Which major investors are selling Synlogic stock?

SYBX stock was sold by a variety of institutional investors in the last quarter, including Dimensional Fund Advisors LP, BlackRock Inc., and Jane Street Group LLC.
View insider buying and selling activity for Synlogic
or view top insider-selling stocks.

Which major investors are buying Synlogic stock?

SYBX stock was bought by a variety of institutional investors in the last quarter, including Renaissance Technologies LLC, Monticello Wealth Management LLC, Flagship Harbor Advisors LLC, and Verition Fund Management LLC.
View insider buying and selling activity for Synlogic
or or view top insider-buying stocks.

How do I buy shares of Synlogic?

Shares of SYBX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Synlogic's stock price today?

One share of SYBX stock can currently be purchased for approximately $3.99.

How much money does Synlogic make?

Synlogic has a market capitalization of $138.99 million and generates $2.22 million in revenue each year. The biotechnology company earns $-51,370,000.00 in net income (profit) each year or ($1.70) on an earnings per share basis.

How many employees does Synlogic have?

Synlogic employs 76 workers across the globe.

What is Synlogic's official website?

The official website for Synlogic is www.synlogictx.com.

Where are Synlogic's headquarters?

Synlogic is headquartered at 301 Binney St. Suite 402, Cambridge MA, 02142.

How can I contact Synlogic?

Synlogic's mailing address is 301 Binney St. Suite 402, Cambridge MA, 02142. The biotechnology company can be reached via phone at 617-401-9975 or via email at [email protected]

This page was last updated on 3/3/2021 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.